Figure 3
ELISA analysis for HCMVpp65422-439, TAF9134-144, and TAF9-specific IgG purified from pooled sera of immunized mice at 10-12 weeks after immunization or patients with SLE. ELISA analysis for anti-HCMVpp65422-439, anti-TAF9134-144, anti-TAF9, and anti-dsDNA activities using purified IgG from (a) immunized mice sera and (b) human SLE sera. A total of 1 μg anti-HCMVpp65422-439 or anti-TAF9134-144 IgG antibody, or 100 μl eluted anti-TAF9 IgG fraction (1 ml/tube) was used. ELISA competitive analysis for anti-HCMVpp65422-439, anti-TAF9134-144, and anti-TAF9 activities using purified IgG from the sera of (c–e) immunized mice and (f–h) human SLE sera. For the competitive assay, 2 μg/well HCMVpp65422-439, TAF9134-144, dsDNA or TAF9 protein was used as competitor agents. Data are shown as the mean ± SEM of three independent experiments.
